The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and commercialization We have received an uptick in questions related to this substance. We felt it was best to share our policy here to bring attention to it. . OCB adheres to WADA guidelines The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions FDA May Reverse Ban on 14 PeptidesWhat It Means for Your Beauty Routine Allure RFK Jr. and the Perils of Peptides Washington Monthly